The 2026 AAPS National Biotechnology Conference (NBC) will be held May 11–14, 2026, at the Sheraton San Diego Hotel & Marina in San Diego, California. This premier event brings together pharmaceutical scientists, researchers, and industry leaders to discuss the latest advancements in biotherapeutics, biologics, and advanced therapies, with a focus on emerging trends, AI/ML-driven workflows, and innovative manufacturing technologies.
Building on past successes, AAPS NBC offers a unique opportunity for attendees to gain scientific insights, connect with peers, and explore practical solutions across bioanalysis, development, and regulatory strategies.
AAPS NBC 2026
📅 May 11–14, 2026
📍 San Diego, CA, USA
Visit Eurofins Clinical Trial Solutions at Booth #402
Connect with the Eurofins Clinical Trial Solutions team at Booth 402 to learn how our global bioanalytical capabilities support complex clinical development programs for biologics and advanced therapies.
Our scientific teams provide expertise across:
LC-MS bioanalysis
Ligand-binding assays
Biomarker testing
Immunogenicity assessments
Support for gene and cell therapy programs
By combining scientific expertise with regulatory experience and operational excellence, we help sponsors generate reliable bioanalytical data that supports confident decision-making throughout drug development.
Schedule time with our experts to discuss upcoming studies, scientific challenges, and strategies to advance your bioanalytical programs.
REQUEST A MEETING
Eurofins Clinical Trial Solutions is proud to share that Kirthi Kutumbaka, PhD, Associate Director, R&D, will be presenting at the AAPS National Biotechnology Conference (NBC) 2026.
Presentation Title
Validated WES Assay for Biomarker Discovery and Clinical Development
📅 Thursday, May 14, 2026
⏰ 9:30 AM – 10:00 AM
This presentation will highlight approaches to biomarker discovery and clinical development using a validated WES assay, demonstrating how advanced analytical technologies can support more robust biomarker strategies in modern drug development.
Kirthi will also discuss the application of CLSI H62 guidance to the validation of high-parameter spectral flow cytometric assays, helping ensure analytical rigor and reproducibility in complex flow cytometry–based biomarker studies.
Attending the session? Visit the Eurofins Clinical Trial Solutions team at Booth 402 to continue the discussion and learn more about our biomarker and bioanalytical capabilities.
The following Eurofins Clinical Trial Solutions experts will be attending AAPS NBC and available to discuss your bioanalytical needs:
Attending AAPS NBC? Connect with the Eurofins Clinical Trial Solutions team onsite to discuss your upcoming studies, bioanalytical challenges, and strategies to support your clinical development programs.